Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New outlook for treatment for bile duct cancer
drugs (stock image)
"We are excited by these results because these drugs are already being tested in clinical trials for other types of cancer and could be beneficial for patients with cholangiocarcinoma.”
Scientists testing experimental drugs that target a key tumour growth pathway

Those with cancer of the bile duct could soon be helped by a new class of experimental drug, a study led by the University of Edinburgh has revealed.

Scientists have discovered that a key pathway, known as wnt, is the driving force behind the growth of tumours in bile duct cancer.

Experimental drugs that block the wnt pathway are already being tested in patients with other cancers, but this is the first sign that bile duct cancer could also be treated in this way.

Researchers discovered that the treatment stopped the bile duct cancer cells from growing in the lab and shrank tumours in animals with the disease. They are now preparing to test whether these drugs will be effective in human patients.

The bile ducts are a series of tubes that drain toxins from the liver. Bile duct cancer, known as cholangiocarcinoma, is often diagnosed at an advanced stage, making it very difficult to treat with surgery. It typically does not respond to chemotherapy and fewer that one in twenty patients will survive for five years after diagnosis.

Professor Stuart Forbes from the MRC Centre for Regenerative Medicine at the University of Edinburgh, said: “We are excited by these results because these drugs are already being tested in clinical trials for other types of cancer and could be beneficial for patients with cholangiocarcinoma.”
 
Dr Luke Boulter from the MRC Human Genetics Unit at the University of Edinburgh, said: “Identifying the signals that control bile duct cancer’s growth will allow us to design better treatments that are urgently needed.”
 
Helen Moremont, chairman trustee of AMMF, The Cholangiocarcinoma Charity, said: “This is potentially very exciting. Cholangiocarcinoma is an under-researched, much neglected but truly devastating disease, so it is good to see progress being made in novel areas.  We are hopeful that this research work with wnt will provide a real step forward towards a clinical trial and some long awaited possible improvements in treatment.”  

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.